论文部分内容阅读
用标准的~(51)Cr 释放法观察了12例急性白血病及白血病前期(MDS)患者的外周单个核细胞(PBMNCs)经重组白细胞介素-2(rIL-2)诱导3～4周后 NK活性及 LAK 活性的变化。结果诱导前 NK 活性(5.3±4.5%)较健康人(56.2±9.9%)明显减低(P<0.01)。rIL-2(1000u//ml)诱导3～4周后 NK 活性(46.9±8.6%)较培养前显著提高(P<0.01)。LAK 活性由0.80±0.83%升高到49.4±9.6%。同时在培养过程中也观察到淋巴细胞逐渐增多,而白血病幼稚细胞逐渐减少。这提示 rIL-2在体外能够逆转急性白血病及 MDS 患者 NK 杀伤功能缺陷,其 LAK 活性的诱导过程也是对白血病细胞的清除过程。
Peripheral blood mononuclear cells (PBMNCs) from 12 acute leukemia and pre-leukemia patients (PBMNCs) were induced by recombinant interleukin-2 (rIL-2) 3 to 4 weeks after NK release Activity and LAK activity changes. Results The NK activity before induction (5.3 ± 4.5%) was significantly lower than that of healthy people (56.2 ± 9.9%) (P <0.01). NK activity (46.9 ± 8.6%) after 3 ~ 4 weeks induction of rIL-2 (1000u // ml) was significantly higher than that before culture (P <0.01). LAK activity increased from 0.80 ± 0.83% to 49.4 ± 9.6%. At the same time, lymphocytes were also observed in the process of gradual increase, while leukemia naive cells gradually decreased. This suggests that rIL-2 in vitro can reverse the acute killer disease in patients with acute leukemia and MDS, and the induction of LAK activity is also the process of leukemia cells.